Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

Merck & Co. patents HIV integrase inhibitors

Dec. 23, 2019

New HIV integrase inhibitors identified at Shionogi

Dec. 17, 2019

New long-acting HIV-1 fusion inhibitor-based regimen developed

Dec. 13, 2019

Improbability research yields path to HIV vaccine

Dec. 13, 2019

FDA clears IND application for first-in-human study of CPT-31

Dec. 11, 2019

World AIDS Day: Immediate ART initiation for neonates with HIV-1 provides significant benefits

Dec. 2, 2019

Less can be more for HIV vaccines, in several ways

Nov. 27, 2019

ViiV Healthcare synthesizes prodrugs of HIV maturation inhibitors

Nov. 15, 2019

Mologen announces the initiation of phase IIa TITAN combination trial

Nov. 8, 2019

Broad strategy for HIV bnAbs

Nov. 5, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...